Literature DB >> 17260017

FRMD3, a novel putative tumour suppressor in NSCLC.

D Haase1, M Meister, T Muley, J Hess, S Teurich, P Schnabel, B Hartenstein, P Angel.   

Abstract

Lung cancer including non-small cell lung carcinoma (NSCLC) represents a leading cause of cancer death in Western countries. Yet, understanding its pathobiology to improve early diagnosis and therapeutic strategies is still a major challenge of today's biomedical research. We analyzed a set of differentially regulated genes that were identified in skin cancer by a comprehensive microarray study, for their expression in NSCLC. We found that ferm domain containing protein 3 (FRMD3), a member of the protein 4.1 superfamily, is expressed in normal lung tissue but silenced in 54 out of 58 independent primary NSCLC tumours compared to patient-matched normal lung tissue. FRMD3 overexpression in different epithelial cell lines resulted in a decreased clonogenicity as measured by colony formation assay. Although cell attachment capabilities and cell proliferation rate remained unchanged, this phenotype was most likely owing to induced apoptosis. Our data identify FRMD3 as a novel putative tumour suppressor gene suggesting an important role in the origin and progression of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260017     DOI: 10.1038/sj.onc.1210225

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  Recent progress in the genetics of diabetic microvascular complications.

Authors:  Yi-Cheng Chang; Emily Yun-Chia Chang; Lee-Ming Chuang
Journal:  World J Diabetes       Date:  2015-06-10

2.  Brucella melitensis and Mycobacterium tuberculosis depict overlapping gene expression patterns induced in infected THP-1 macrophages.

Authors:  M Masoudian; A Derakhshandeh; M M Ghahramani Seno
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

Review 3.  The role of the basal stem cell of the human breast in normal development and cancer.

Authors:  Jose Russo; Irma H Russo
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

4.  Roles of Cadherin2 in Thyroid Cancer.

Authors:  Yun Chen; Chaojin Hong; Qihao Zhou; Zhiquan Qin
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

5.  Estimating Shared Copy Number Aberrations for Array CGH Data: The Linear-Median Method.

Authors:  Y-X Lin; V Baladandayuthapani; V Bonato; K-A Do
Journal:  Cancer Inform       Date:  2010-10-12

6.  Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors.

Authors:  Shirley K Knauer; Verena Fetz; Jens Rabenstein; Sandra Friedl; Bettina Hofmann; Samaneh Sabiani; Elisabeth Schröder; Lena Kunst; Eugen Proschak; Eckhard Thines; Thomas Kindler; Gisbert Schneider; Rolf Marschalek; Roland H Stauber; Carolin Bier
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

7.  rs1888747 polymorphism in the FRMD3 gene, gene and protein expression: role in diabetic kidney disease.

Authors:  Marjoriê P Buffon; Mariana P Carpena; Denise A Sortica; Andressa Santer; Rodrigo Carlessi; Bianca M de Souza; Maria I Edelweiss; Milton Berger; Daisy Crispim; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2016-01-08       Impact factor: 3.320

8.  Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly.

Authors:  Anna Tervasmäki; Tuomo Mantere; Leila Eshraghi; Niina Laurila; Hanna Tuppurainen; Veli-Pekka Ronkainen; Susanna Koivuluoma; Raman Devarajan; Hellevi Peltoketo; Katri Pylkäs
Journal:  Int J Cancer       Date:  2019-03-21       Impact factor: 7.396

9.  Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility.

Authors:  Indra Adrianto; Chee Paul Lin; Jessica J Hale; Albert M Levin; Indrani Datta; Ryan Parker; Adam Adler; Jennifer A Kelly; Kenneth M Kaufman; Christopher J Lessard; Kathy L Moser; Robert P Kimberly; John B Harley; Michael C Iannuzzi; Benjamin A Rybicki; Courtney G Montgomery
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

10.  High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT.

Authors:  Tzu-Ju Chen; Chia-Lin Chou; Yu-Feng Tian; Cheng-Fa Yeh; Ti-Chun Chan; Hong-Lin He; Wan-Shan Li; Hsin-Hwa Tsai; Chien-Feng Li; Hong-Yue Lai
Journal:  Int J Clin Oncol       Date:  2021-05-27       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.